|
Jun 24
|
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
|
|
Jun 20
|
Madrigal poised to enter European MASH market after CHMP endorsement
|
|
Jun 20
|
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount
|
|
Jun 20
|
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
|
|
Jun 17
|
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 16
|
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
|
|
Mar 11
|
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
|
|
Feb 21
|
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
|
|
Feb 12
|
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
|
|
Jan 3
|
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Nov 15
|
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
|
|
Nov 11
|
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
|
|
Nov 10
|
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
|
|
Oct 9
|
High Growth Tech Stocks To Watch In October 2024
|
|
Oct 2
|
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
|
|
Oct 1
|
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
|
|
Sep 30
|
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
|
|
Jul 24
|
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 12
|
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
|